Genmab AS (CHIX:GMABC) Other Current Assets: kr0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:GMABC Genmab AS CHIX:GMABC
95 GF Score
Price kr1,874.50
GF Value kr2,310.53
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Genmab AS Other Current Assets?

Genmab AS CHIX:GMABC -1.42% 95 Other Current Assets is kr0 Mil as of Mar. 2026. GuruFocus rates CHIX:GMABC with a GF Score™ of 95/100 and a GF Value™ of kr2,310.53 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Genmab AS's other current assets for the quarter that ended in Mar. 2026 was kr0 Mil.

Genmab AS's quarterly other current assets stayed the same from Sep. 2025 (kr0 Mil) to Dec. 2025 (kr0 Mil) but then increased from Dec. 2025 (kr0 Mil) to Mar. 2026 (kr0Mil).

Genmab AS's annual other current assets declined from Dec. 2023 (kr0 Mil) to Dec. 2024 (kr-0 Mil) increased from Dec. 2024 (kr-0 Mil) to Dec. 2025 (kr0 Mil).


Genmab AS Other Current Assets Related Terms


Genmab AS Other Current Assets Historical Data

* Premium members only.

The historical data trend for Genmab AS's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab AS Other Current Assets Chart

Genmab AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.00 0.00

Genmab AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 0.00 0.00 0.00 0.00
CHIX:GMABC
95GF Score
Genmab AS CHIX:GMABC
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genmab AS Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of kr0 Mil mean?
Genmab AS (CHIX:GMABC) has a Other Current Assets of kr0 Mil as of Mar. 2026. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Genmab AS.
Is Genmab AS's Other Current Assets too high?
Genmab AS's current Other Current Assets is kr0 Mil. Overall, Genmab AS has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Other Current Assets compare to VRTX and REGN?
Genmab AS's Other Current Assets of kr0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Biotechnology company?
A good Other Current Assets depends on the Biotechnology industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Genmab AS. Genmab AS's current Other Current Assets is kr0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (CHIX:GMABC) is currently considered Modestly Undervalued. The stock's GF Value™ is kr2,310.53, compared to a current price of kr1,874.50 — trading 18.9% below its estimated fair value. The current Other Current Assets is kr0 Mil. Genmab AS's overall GF Score™ is 95/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For Genmab AS (CHIX:GMABC), the current Other Current Assets is kr0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genmab AS (CHIX:GMABC) Overvalued in 2026?

Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued. The current stock price of kr1,874.50 is trading 18.9% below its estimated GF Value™ of kr2,310.53. GuruFocus considers Genmab AS to be Modestly Undervalued.

Key valuation signals for CHIX:GMABC:

  • Other Current Assets: kr0 Mil
  • GF Value™: kr2,310.53 vs. price of kr1,874.50 (18.9% below fair value)
  • GF Score™: 95/100 with 5 warning signs

No single metric tells the full story. See the CHIX:GMABC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genmab AS Business Description

Address Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
95GF Score

Get the complete analysis for CHIX:GMABC

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1,874.50
Price
kr2,310.53
GF Value